Genetics Institute, Inc.

Other

Wyeth

Gray D Shaw

Dianne S Sako

Ravindra Kumar

Geertruida Machteld Veldman

Glenn R Larsen

Dale Anthony Cumming

Xiao-Jia Chang

Jasbir S Seehra

Amechand Boodhoo

Nadine Weich

Francis Sullivan

Ray Camphausen

Meike Lorenz

Ron Kriz

Tom McDonagh

Joseph Lawrence Wooters

Jin Xu

Methods of using soluble tandem selectin glycoprotein ligand (TSGL) and TSGL fusion proteins, such as TSGL-Ig, in combination with T cell activation therapies or an adoptive cell transfer (ACT) therapy.

Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof

Lysine-depleted variants of fragment crystallizable (Fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of N-terminal targeting or active peptide domains fused with such lysine-depleted variant IgG-Fc domains. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.

Variants of IgG Fc with limited amine groups

Conjugated lysine-depleted variants of fragment crystallizable (Fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of C-terminal targeting peptide sequences, fused to such lysine-depleted variant IgG-Fc domains. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.

Variants of IgG-Fc fusion that provide for site-specific conjugation at the N-terminus

Provided herein are methods and compositions, including pharmaceutical compositions, for treating thrombosis, vascular inflammation, and thrombocytopenia. The methods and compositions of the present invention are also useful for extending the useful storage shelf life of platelets.

Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets

Recombinant proteins comprised of multiple selectin binding domains derived from the glycopeptide PSGL-1, in a novel tandem configuration, are disclosed, including their fusions with immunoglobulins and/or other polypeptides. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.

Soluble tandem selectin glycoprotein ligand molecules

A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.

P-selectin ligand protein

Nucleic acids encoding P-selectin ligand fusion proteins

The present invention provides compositions and methods for treating or preventing vascular-associated disorders.

Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof

The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLIC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLIC-1 gene has been introduced or disrupted. The invention still further provides isolated SLIC-1 proteins, fusion proteins, antigenic peptides and anti-SLIC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Selectin ligand interactor cytoplasmic (SLIC-1), a P-selectin glycoprotein ligand (PSGL-1) binding protein

Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor.

Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof

Platelet glycoprotein Ib&#x3b1; fusion polypeptides and methods of use thereof

Platlet glycoprotein IB&#x3b1; fusion polypeptides and methods of use thereof

Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.

Growing community of inventors

Milton, MA, United States of America

Gray D Shaw